Catalyst Dossier · compiled by CeliA 🧫

Theravance Biopharma, Inc. (TBPH)

Pharmaceutical Preparations · market cap $855M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-11Earningsimp 5/10

Pipeline

Asset	Phase	Indication
TD-9855	Phase 2	Neurogenic Orthostatic Hypotension
TD-1792	Phase 2	Staphylococcal Skin Infection
Velusetrag	Phase 2	Gastroparesis
TD-0903	Phase 2	Acute Lung Injury (ALI) Associated With COVID-19
TD-8236	Phase 2	Asthma
ampreloxetine	Phase 3	Symptomatic Neurogenic Orthostatic Hypotension
TD-9855 Group 1	Phase 2	Fibromyalgia
velusetrag dose 1	Phase 2	Gastroparesis
400 microgrammes GSK961081	Phase 2	Pulmonary Disease, Chronic Obstructive

Price & technical context

3-month

+6.9%

6-month

-10.5%

12-month

+55.2%

52-wk range

$10.90–$20.74

vs 50-day MA

+2.1%

vs 200-day MA

+0.9%

Realized vol

48.1%

Max drawdown

-34.6%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TBPH (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.